How RGCC’s CTC isolation technology is unique

Cancer is a systemic disease, especially in advanced cases. This means it can spread to diâerent locations in the body and exhibit variations in behavior at each site. Circulating tumor cells (CTCs) serve as a crucial link between the primary tumor and metastatic sites.

We know that CTCs themselves are relatively rare, representing approximately 1 cell per 100,000 to 1 cell per 1,000,000 white blood cells (WBCs). However, CTCs are heterogeneous (diverse in character), and despite their low numbers, they can include cancer stem cells (CSCs), which have tumorigenic properties.

Understanding the relationship between CTCs and CSCs is essential, as CSCs are a subset of CTCs. Cancer is a complex disease with causes at the genomic, genetic, and proteomic levels. Therefore, comprehensive information about tumor behavior requires a combination of methodologies, including genomic, transcriptomic, and cellular assays, applied to the connective entity that links all disease sites.

RGCC oâers a solution by combining CTC isolation technology with an analytical platform to detect active mutations, analysis of the gene expressions, along with cytotoxicity assays for medications (in their active form).

This approach provides clinicians with a comprehensive overview of the disease's features and its response to various therapeutic agents, including, but not limited to targeted therapies, and checkpoint inhibitors (which cannot be easily assessed by cytotoxicity assays).